article · PubMed
OBJECTIVE: We describe the development of a probiotic-infused carbamazepine dosage form. This dosage form combines carbamazepine with probiotics, proposing the potential use of both active pharmaceutical ingredients in a single dosage form. DESIGN: was resistant to carbamazepine, prompting its selection for development of the dosage form. A suspension was formulated using the precipitation method with stability testing assessing organoleptic properties, pH, and viability of the bacteria in the dosage form. Toxicity assessment was done using 20 male albino Wistar rats, measuring weight, urination, and anxiety changes postadministration of carbamazepine and probiotics, following ethical approval from the University of Zimbabwe's animal house laboratory and board. RESULTS: viability over a period of 28 days. CONCLUSION: Integrating probiotics into carbamazepine formulations offers a promising strategy, with potential applications to other antiepileptic drugs.
This page summarises published work. The authoritative version sits with the publisher.
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
